TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Up 12.1% – Still a Buy?

TransCode Therapeutics Inc. (NASDAQ:RNAZ) shares traded up 12.1% during trading on Monday. The stock traded as high as $1.87 and last traded at $1.76. 65,703 shares traded hands during mid-day trading, an increase of 40% from the average session volume of 46,933 shares. The stock had previously closed at $1.57.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, TransCode Therapeutics currently has an average rating of “Sell”.

TransCode Therapeutics Price Performance

The company has a market capitalization of $29.21 million, a price-to-earnings ratio of -0.03 and a beta of 1.25. The business has a fifty day moving average price of $2.58 and a 200 day moving average price of $5.59.

TransCode Therapeutics (NASDAQ:RNAZ) last released its earnings results on Friday, August 14th. The company reported ($7.17) EPS for the quarter.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc is a clinical-stage biotechnology company focused on developing RNA-based medicines for the treatment of cancer, particularly metastatic disease. The company’s approach is designed to use targeted therapeutic agents to interfere with biological processes that enable cancer cells to spread.

Its lead product candidate, TTX-MC138, is an investigational therapy designed to target microRNA-10b, a molecule associated with the development and progression of metastatic tumors.